glp 1 agonist vision loss GLP-1s and Eye Health: What You Need to Know GLP-1 drugs and vision loss:

Drp1-mediated mitochondrial abnormalities link to synaptic injury in diabetes model

In addition to the drugs potential direct implications in treating those conditions, employers also are considering the possible longer-term health effects of treating obesity, such as reduced risk of chronic conditions which can lower health costs in the future given the prevalence of obesity and the cost of not treating it, Schuman said

Retatrutide is the unimolecular triple agonist furthest in development and data from phase 2 trials suggests that this may soon become the most potent weight-lowering pharmacotherapy to be licenced

2013c;38(8):125970

this difference may result from a ~5x stronger effect produced by GLP-1 analogs, compared to DPP-4 inhibitors (Charbonnel & Cariou, 2011) No change in weight Contraindications: type I diabetes (these patients lack pancreatic beta cells) diabetic ketoacidosis (it would not be effective for treating this condition) an association between DPP-4 inhibitors and heart failure has been observed for two members of this drug class in patients with type 2 DM and atherosclerosis

Notably, compound 30 (Figure 5) exhibited strong activity, with 56.8% inhibition at 10 M